Symptom relief evidence; mucosal healing and remission not demonstrated
Inflammatory bowel disease (Crohn's disease and ulcerative colitis) is one of the most common reasons for medical cannabis use among GI patients. Cannabis reduces IBD symptoms — pain, nausea, appetite loss, and diarrhea — but has not demonstrated mucosal healing or disease remission in RCTs. The CB2 receptor pathway in gut immune cells is a major research target for IBD-specific cannabinoid therapies.
Medical Disclaimer: IBD requires specialist gastroenterological care. Cannabis should not replace disease-modifying therapies. Chronic cannabis use can cause cannabinoid hyperemesis syndrome. Consult your gastroenterologist before using cannabis.
IBD affects approximately 6.8 million people globally and is characterized by chronic intestinal inflammation causing abdominal pain, diarrhea, rectal bleeding, weight loss, and fatigue. Conventional treatments (aminosalicylates, corticosteroids, immunomodulators, biologics) achieve remission in many patients but leave a significant treatment gap. The endocannabinoid system is highly expressed in the gut: CB1 receptors on enteric neurons regulate gut motility and pain; CB2 receptors on intestinal immune cells regulate inflammation; and endocannabinoids (AEA, 2-AG) modulate intestinal permeability and immune activation. Cannabis use is reported by 12–17% of IBD patients, primarily for pain, nausea, and appetite. Observational studies consistently show symptom improvement with cannabis use. However, RCTs have been disappointing for disease modification: a 2013 Naftali trial of inhaled cannabis in Crohn's disease showed significant symptom improvement but no reduction in inflammatory markers or mucosal healing. A 2021 RCT of CBD in Crohn's disease showed no benefit vs. placebo. The disconnect between symptom relief and disease modification is a key challenge in IBD cannabinoid research. CBG shows particular promise for IBD in preclinical models via CB2 agonism and anti-inflammatory mechanisms.
Evidence summary for cannabinoid-based interventions in Inflammatory Bowel Disease.
Mechanism: CB1 agonism reduces gut motility, pain, and nausea; CB2 agonism on intestinal immune cells reduces inflammation; endocannabinoid enhancement reduces intestinal permeability
Clinical Status: Multiple observational studies showing symptom relief; RCTs show symptom improvement without mucosal healing
Effective for symptom management (pain, nausea, appetite). Does not appear to reduce intestinal inflammation or promote mucosal healing in RCTs. Risk of cannabis use disorder in chronic IBD patients.
Mechanism: Anti-inflammatory via CB2 receptors and TRPV1; reduces intestinal permeability; antioxidant effects
Clinical Status: 2021 RCT in Crohn's disease showed no benefit vs. placebo; ongoing trials in UC
A 2021 RCT (Irving et al.) found CBD did not improve Crohn's disease activity vs. placebo. Ongoing trials in ulcerative colitis. Non-psychoactive and generally well-tolerated.
Mechanism: CB2 partial agonism, α2-adrenoceptor agonism, and 5-HT1A antagonism reduce intestinal inflammation; reduces nitric oxide and pro-inflammatory cytokines in colitis models
Clinical Status: Preclinical evidence in colitis models; no completed human trials
Most promising cannabinoid for IBD based on preclinical data. Reduces colon weight, myeloperoxidase activity, and inflammatory markers in murine colitis. Human trials needed.
Peer-reviewed research on cannabinoids and Inflammatory Bowel Disease.
Naftali T, Bar-Lev Schleider L, Dotan I, et al. · Clinical Gastroenterology and Hepatology
Inhaled cannabis (115mg THC/day) produced clinical response in 10/11 Crohn's patients vs. 4/10 placebo. Complete remission in 5/11 vs. 1/10. No significant change in inflammatory markers (CRP, calprotectin).
View on DOI.orgBorrelli F, Fasolino I, Romano B, et al. · Biochemical Pharmacology
CBG significantly reduced colon weight, macroscopic damage, and pro-inflammatory cytokines in a murine colitis model, proposing CBG as a candidate for IBD clinical trials.
View on DOI.orgIrving PM, Iqbal T, Nwokolo C, et al. · Inflammatory Bowel Diseases
CBD (10mg twice daily for 8 weeks) did not maintain remission or improve Crohn's disease activity vs. placebo. No significant difference in CDAI scores or inflammatory markers.
View on DOI.orgCannabis reduces Crohn's symptoms (pain, nausea, appetite) but has not demonstrated mucosal healing or remission induction in RCTs. It is used by many Crohn's patients for symptom management but should not replace conventional disease-modifying therapies.
Evidence for UC is similar to Crohn's — symptom relief without demonstrated mucosal healing. Observational studies show UC patients report symptom improvement with cannabis. RCT evidence is limited. Ongoing trials are evaluating CBD and other cannabinoids for UC.
Yes. Chronic heavy cannabis use is associated with cannabinoid hyperemesis syndrome (CHS) — a condition of cyclic vomiting that paradoxically improves with hot showers and resolves with cannabis cessation. Cannabis can also cause diarrhea, nausea, and appetite changes.
A 2021 RCT found CBD did not improve Crohn's disease activity. Possible reasons include: the dose used (10mg twice daily) may be too low; CBD may not adequately penetrate inflamed intestinal tissue; or the anti-inflammatory mechanisms of CBD may not be sufficient to overcome the complex immune dysregulation in Crohn's. Higher doses and different formulations are being studied.
